Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
Research ArticleOriginal Article
Open Access

Clinical characteristics and in-hospital mortality of COVID-19 adult patients in Saudi Arabia

Samah I. Abohamr, Rami M. Abazid, Mubarak A. Aldossari, Hala A. Amer, Omar S. Badhawi, Obaid M. Aljunaidi, Shaimaa H. Alzarzour, Hiba M. Saadeddin, Fayaz A. Bhat and Eman Elsheikh
Saudi Medical Journal November 2020, 41 (11) 1217-1226; DOI: https://doi.org/10.15537/smj.2020.11.25495
Samah I. Abohamr
From the Heart Health Center (Abohamr, Aldossari, Badhawi, Aljunaidi, Saadeddin, Bhat); from the Department of Prevention and Control of Infection (Amer, Alzarour), King Saud Medical City, Riyadh; from the Internal Medicine Department (Elsheikh), King Faisal University, Alahsa, Kingdom of Saudi Arabia; from Division of Nuclear Medicine, Section of Cardiac Hybrid Imaging, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada,(Abazid); from the Department of Cardiology (Abohamr, Elsheikh), Tanta University Hospital, Tanta; and from the Community Medicine Department (Amer), National Research Center, Giza, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rami M. Abazid
From the Heart Health Center (Abohamr, Aldossari, Badhawi, Aljunaidi, Saadeddin, Bhat); from the Department of Prevention and Control of Infection (Amer, Alzarour), King Saud Medical City, Riyadh; from the Internal Medicine Department (Elsheikh), King Faisal University, Alahsa, Kingdom of Saudi Arabia; from Division of Nuclear Medicine, Section of Cardiac Hybrid Imaging, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada,(Abazid); from the Department of Cardiology (Abohamr, Elsheikh), Tanta University Hospital, Tanta; and from the Community Medicine Department (Amer), National Research Center, Giza, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mubarak A. Aldossari
From the Heart Health Center (Abohamr, Aldossari, Badhawi, Aljunaidi, Saadeddin, Bhat); from the Department of Prevention and Control of Infection (Amer, Alzarour), King Saud Medical City, Riyadh; from the Internal Medicine Department (Elsheikh), King Faisal University, Alahsa, Kingdom of Saudi Arabia; from Division of Nuclear Medicine, Section of Cardiac Hybrid Imaging, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada,(Abazid); from the Department of Cardiology (Abohamr, Elsheikh), Tanta University Hospital, Tanta; and from the Community Medicine Department (Amer), National Research Center, Giza, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hala A. Amer
From the Heart Health Center (Abohamr, Aldossari, Badhawi, Aljunaidi, Saadeddin, Bhat); from the Department of Prevention and Control of Infection (Amer, Alzarour), King Saud Medical City, Riyadh; from the Internal Medicine Department (Elsheikh), King Faisal University, Alahsa, Kingdom of Saudi Arabia; from Division of Nuclear Medicine, Section of Cardiac Hybrid Imaging, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada,(Abazid); from the Department of Cardiology (Abohamr, Elsheikh), Tanta University Hospital, Tanta; and from the Community Medicine Department (Amer), National Research Center, Giza, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omar S. Badhawi
From the Heart Health Center (Abohamr, Aldossari, Badhawi, Aljunaidi, Saadeddin, Bhat); from the Department of Prevention and Control of Infection (Amer, Alzarour), King Saud Medical City, Riyadh; from the Internal Medicine Department (Elsheikh), King Faisal University, Alahsa, Kingdom of Saudi Arabia; from Division of Nuclear Medicine, Section of Cardiac Hybrid Imaging, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada,(Abazid); from the Department of Cardiology (Abohamr, Elsheikh), Tanta University Hospital, Tanta; and from the Community Medicine Department (Amer), National Research Center, Giza, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Obaid M. Aljunaidi
From the Heart Health Center (Abohamr, Aldossari, Badhawi, Aljunaidi, Saadeddin, Bhat); from the Department of Prevention and Control of Infection (Amer, Alzarour), King Saud Medical City, Riyadh; from the Internal Medicine Department (Elsheikh), King Faisal University, Alahsa, Kingdom of Saudi Arabia; from Division of Nuclear Medicine, Section of Cardiac Hybrid Imaging, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada,(Abazid); from the Department of Cardiology (Abohamr, Elsheikh), Tanta University Hospital, Tanta; and from the Community Medicine Department (Amer), National Research Center, Giza, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaimaa H. Alzarzour
From the Heart Health Center (Abohamr, Aldossari, Badhawi, Aljunaidi, Saadeddin, Bhat); from the Department of Prevention and Control of Infection (Amer, Alzarour), King Saud Medical City, Riyadh; from the Internal Medicine Department (Elsheikh), King Faisal University, Alahsa, Kingdom of Saudi Arabia; from Division of Nuclear Medicine, Section of Cardiac Hybrid Imaging, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada,(Abazid); from the Department of Cardiology (Abohamr, Elsheikh), Tanta University Hospital, Tanta; and from the Community Medicine Department (Amer), National Research Center, Giza, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiba M. Saadeddin
From the Heart Health Center (Abohamr, Aldossari, Badhawi, Aljunaidi, Saadeddin, Bhat); from the Department of Prevention and Control of Infection (Amer, Alzarour), King Saud Medical City, Riyadh; from the Internal Medicine Department (Elsheikh), King Faisal University, Alahsa, Kingdom of Saudi Arabia; from Division of Nuclear Medicine, Section of Cardiac Hybrid Imaging, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada,(Abazid); from the Department of Cardiology (Abohamr, Elsheikh), Tanta University Hospital, Tanta; and from the Community Medicine Department (Amer), National Research Center, Giza, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fayaz A. Bhat
From the Heart Health Center (Abohamr, Aldossari, Badhawi, Aljunaidi, Saadeddin, Bhat); from the Department of Prevention and Control of Infection (Amer, Alzarour), King Saud Medical City, Riyadh; from the Internal Medicine Department (Elsheikh), King Faisal University, Alahsa, Kingdom of Saudi Arabia; from Division of Nuclear Medicine, Section of Cardiac Hybrid Imaging, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada,(Abazid); from the Department of Cardiology (Abohamr, Elsheikh), Tanta University Hospital, Tanta; and from the Community Medicine Department (Amer), National Research Center, Giza, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eman Elsheikh
From the Heart Health Center (Abohamr, Aldossari, Badhawi, Aljunaidi, Saadeddin, Bhat); from the Department of Prevention and Control of Infection (Amer, Alzarour), King Saud Medical City, Riyadh; from the Internal Medicine Department (Elsheikh), King Faisal University, Alahsa, Kingdom of Saudi Arabia; from Division of Nuclear Medicine, Section of Cardiac Hybrid Imaging, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada,(Abazid); from the Department of Cardiology (Abohamr, Elsheikh), Tanta University Hospital, Tanta; and from the Community Medicine Department (Amer), National Research Center, Giza, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

Objectives: To provide a detailed study of demographic, baseline comorbidities, clinical features, and outcome for Coronavirus disease 2019 (COVID-19) patients.

Methods: A record-based case-series study conducted from March 23 to June 15, 2020 in King Saud Medical City, Riyadh, Saudi Arabia. Demographic data, clinical presentation, laboratory investigations, complications, and in-hospital outcome of COVID-19 patients collected with analysis of the clinical characteristics for survivors and deceased.

Results: A total of 768 patients were included. The mean age was 46.36±13.7 years and 76.7% were men. Approximately 96.3% reported more than one comorbidity; diabetes mellitus was the most frequent (46.4%). Fever (84.5%), cough (82.3%), and shortness of breath (79.8%) were the main presenting symptoms. During the follow-up, pneumonia reported in 68.6%, acute respiratory distress syndrome in 32.7%, septic shock in 20.7%, respiratory failure in 20.3%, and acute kidney injury in 19.3%. Approximately 45.8% of enrolled patients required intensive care unit admission. Lung disease (odd ratio [OR]=3.862 with 95% confident interval [CI] (2.455-6.074), obesity (OR=3.732, CI=2.511-5.546), smoking (OR=2.991, CI=2.072-4.317), chronic kidney disease (OR=2.296. CI=1.497-3.521), and diabetes mellitus (OR=2.291, CI=1.714-3.063) are predictors of ICU admission. Fatality ratio was 89/2084 (4.27%). Men were more prevalent in dead group.

Conclusion: Coronavirus disease 2019 places a huge burden on healthcare facilities, particularly in patients with comorbidity. Coronavirus disease 2019 patients who are obese and smokers with history of diabetes mellitus have a high risk of death.

  • COVID-19
  • in-hospital
  • clinical characteristics
  • mortality
  • Saudi Arabia

Coronavirus disease 2019 (COVID-19) outbreaks emerged in December 2019 in Wuhan, China. From there it spread rapidly and threaten many different countries in the world, and was soon declared to be a global pandemic.1-4 Coronavirus disease 2019 is a highly contagious disease that is caused by the 2019 novel coronavirus (SARS-COV-2) from the Orthocoronavirinae family. The virus contains an enveloped, single-stranded RNA, and distinctive “crown-like” spikes on its surface.5 The COVID-19 virus belongs to the same family as the Severe Acute Respiratory Syndrome (SARS-COV) virus, and the Middle East Respiratory Syndrome (MERS-COV) virus. Although it has been reported to be more contagious, its pathogenesis is not fully understood.6,7 The most vital encoded structural protein of COVID-19 is the spike glycoprotein (S) that consists of 3 S1-S2 heterodimers that bind to the angiotensin-converting enzyme 2 (ACE2) receptor on type II pneumocytes.2,8

In the Kingdom of Saudi Arabia, the first COVID-19 case was declared on March 2, 2020, and most of the confirmed cases were due to returning travelers and their immediate contacts. The total number of COVID-19 confirmed cases, by July 14, 2020, increased to approximately 235,000, with a fatality rate of approximately 1%.9,10

The manifestations of COVID-19 are broad, usually starting with non-specific symptoms including fever, a dry cough, and fatigue. The disease can also involve a variety of systems, including the respiratory, neurological, musculoskeletal, and the gastrointestinal systems. The disease also can progress rapidly to acute respiratory distress syndrome (ARDS) in highly risk patients such as the elderly,5 and individuals with other medical comorbidities such as heart, lung, kidney, or liver diseases. Importantly, patients with immunosuppressive disorders may have worse prognoses and higher mortalities due to the earlier development of septic shock, heart failure, arrhythmias, and multi-organ failure.11-13

Information on the clinical characteristics of COVID-19 and its course is rapidly evolving; data are beginning to emerge from retrospective clinical studies conducted worldwide which have focused primarily on epidemiological and clinical characteristics.14,15 However, there have been few reports conducted in the Middle East region.

The aim of this research is to provide a comprehensive analysis of worst-outcome predictors in addition to demographic, baseline comorbidity, and clinical characteristics of hospitalized COVID-19-positive patients in Saudi Arabia.

Methods

A descriptive, record-based case-series single-center study that included all adult patients confirmed with COVID-19 who were hospitalized in King Saud Medical City, Riyadh, Saudi Arabia between March 23 and June 15, 2020. Exclusion criteria were COVID-19 patients with unavailable or incomplete data.

The process of suspicion-to-confirmation of COVID-19 was guided by the Saudi Centers for Disease Control and Prevention guidelines (updated in June 2020) based on the best available data and evidence.16 According to the latest of these guidelines, all patients visiting the emergency department were scored using the Visual Triage Checklist (V1:3, Appendix-I).16 Patients with relevant triage scores were directed to a designated respiratory clinic for full assessment for COVID-19/MERS-CoV based on a surveillance case definition (V1:3, Appendix-II).16 A nasopharyngeal swab sample was collected for COVID-19 laboratory screening using a polymerase chain reaction (PCR) test. Confirmation of a COVID-19 infection was then reported based on a positive PCR result. Patients with confirmed COVID-19 infections and complete clinical and laboratory data were included in our study.

All demographic data, clinical presentation data (including clinical symptoms and signs), comorbidities, laboratory findings, and outcomes were collected from electronic medical records. The laboratory investigations included the PCR results for SARS-CoV-2 infection, complete blood count, cardiac enzymes (troponin I, creatinine kinase [CK], CK-MB), D-dimer, C-reactive protein, prothrombin time, lactate dehydrogenase, glycated hemoglobin (Hb A1C), and liver- and renal-function tests. Clinical outcomes were classified into 3 categories: home-isolation, hospitalization, and death.

In the early stages of this pandemic in Saudi Arabia, hospital admission was mandatory for all suspected cases, and confirmed cases were referred to designated facilities for further follow-up. As the situation evolved, home isolation of suspected and confirmed COVID-19 cases that were clinically stable was allowed if they met certain criteria defined by the Saudi Ministry of Health (Appendix-III).16

This work was performed in compliance with the ethical approval of the Ethical Committee of the King Saud Medical City and the Helsinki Declaration and its amendments by World Medical Association (WMA).

Statistical analyses

The data were analyzed using Microsoft Excel 2016 and Statistical Package for Social Sciences for Windows, version 26 (IBM Corp., Armonk, NY, USA). Continuous (normally distributed) variables were represented as means ± SDs with 95% confidence intervals (CI), and percentiles, frequencies, and percentages were used for categorical variables. Non-normally distributed variables were represented as medians with 25% and 75% values. Student’s t-tests were used to compare means of normally distributed variables between groups, and the Mann-Whitney U test was used for non-normally distributed variables. The χ2 test, or Fisher’s exact test, was used to compare categorical variables between groups. Effect modifications were evaluated by stratification, statistical interaction was assessed by including main predictor variables and their product terms in the binary logistic regression analysis in addition to mutinominal logistic regression analysis. A p-value <0.05 was considered statistically significant.

Results

Baseline characteristics

During the period of our study, 2084 patients were diagnosed with COVID-19. A total of 768 patients with full clinical data sets were included in this study (Figure 1).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

The flowchart of analysis procedure.

The mean age was 46.36 ± 13.7 years and 76.7% were male. The dominant nationality among the patients was non-Saudi (75.5%). Many of the patients (96.3%) had more than one comorbidity. Diabetes mellitus was the most common (46.4%) in patients, followed by hypertension (34.6%), smoking (20.8%), obesity (8.6%), lung disease (14.1%) chronic kidney disease (CKD) (13.5%), history of ischemic heart disease (IHD) (10.7%), and cerebrovascular accident (CVA) (5.9%). Other clinical characteristics are presented in Table 1.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1

Demographics and clinical characteristics of patient (N=768).

Clinical presentation

Patient clinical presentations were variable. The following symptoms were reported: fever (84.5%), cough (82.3%), shortness of breath (79.8%), and diarrhea (21.9%). In addition, 39 patients (5.1%) were diagnosed with acute coronary syndrome (ACS), 32 (4.2%) presented with decompensated heart failure, 7 (0.9%) presented with arrhythmia, and 2 (0.3%) presented with myocarditis. During follow-up, pneumonia was reported in 527 patients (68.6%), ARDS in 251 (32.7%), septic shock in 159 (20.7%), respiratory failure (RF) in 156 (20.3%), and acute kidney injury (AKI) in 148 patients (19.3%) (Table 1).

Management plan and complications

In total, 590 patients (76.8%) were hospitalized due to severe symptoms either in the intensive care unit (ICU; 352; 45.8%) or on a general ward (240; 31.3%). In contrast, 163 patients (21.2%) with mild symptoms were isolated at home and 15 (2.0%) were isolated in hotels (Table 1). We found that patients admitted to the ICU were significantly older than non-ICU admissions (mean 47.4 ± 13.8 years vs 45.5 ± 13.5 years, p=0.05). Males were admitted to the ICU more often than women (284; 80.7% versus 69; 19.3%, p=0.01].

For other comorbidities, we found that ICU admission was significantly associated with smokers compared to non-smokers (p=0.001), obesity (p=0.001), hypertension (p=0.01), CKD (p=0.001), diabetes mellitus (p=0.001), IHD (p=0.03), and lung disease (p=0.001). Reported complications were also significantly higher among ICU admissions when compared to non-ICU admissions for pneumonia (p=0.01), ARDS (p=0.001), septic shock (p=0.001), RF (p=0.001), AKI (p=0.001), and death (p=0.01). Five patients (1.4%) with ARDS admitted to the ICU required treatment with extracorporeal membrane oxygenation (Table 2).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2

Demographics and clinical characteristics of patients regarding Non-intensive care unit (ICU) and ICU admission.

Laboratory results

Patients who were admitted to the ICU had significantly lower hemoglobin levels (p=0.001) and platelet counts (p=0.04), but international normalized ratio (INR), creatinine, and D-dimer values were significantly higher in ICU patients. Other laboratory results are presented in Table 2.

Predictors for ICU admission

Using a univariate regression we found that lung disease, obesity, smoking, CKD, and diabetes mellitus were predictors for ICU admission (Table 3).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 3

Predictors of risk of intensive care unit admission among COVID-19 patients.

Predictors for death

During follow-up, 89 patients (4.27%) died, with males being more prevalent. Demographic and clinical characteristics of deceased patients compared to survived patients are shown in Table 4.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 4

Demographics and clinical characteristics of survived COVID-19 patients compared to deceased patients.

A univariate regression analysis in Table 5 showed that clinical predictors of death were: obesity (p=0.001), history of smoking (p=0.001), and diabetes mellitus (p=0.001).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 5

Predictors of mortality in COVID-19 patients.

Discussion

The present study analyzed the demographics of patients with confirmed COVID-19 infections and found that 76.8% were hospitalized (45.8% requiring ICU admission). The mortality rate was approximately 4.3%. Male gender, ARDS, acute renal failure, and septic shock were major predictors for death.

The COVID-19 outbreak in Saudi Arabia is one of the biggest challenges in the last few decades. Although older patients are more vulnerable for infection, younger patients were predominantly affected here with a mean age of 46.4 years; close to that (47 years) reported previously for the young adults representing the majority of COVID-19-positive patients.15,17,18 Male-gender predominance in our study was also similar to that reported by Huang et al14 and Chen et al.19 A recent report (published May 10, 2020) confirmed that men have higher ACE2 levels than women, and as a consequence of ACE2 helping the virus to infect healthy cells, this may explain why men are more susceptible than women to COVID-19.20 Importantly, multiple comorbidities such as hypertension, diabetes, and cardiovascular disease can predispose patients to a severe form of the disease and various complications.21 Hypertension and diabetes were the most frequently reported comorbidities among COVID-19 patients by Richardson et al22 and likewise, most of our study population had multiple comorbidities. These risk factors can also affect immune-system responses to this infection; a good example is the influence diabetes can have on viral cell-entry and the body’s inflammatory response to the infection.23,24

We have reported that fever, cough, and shortness of breath were the most prevalent clinical presentations in approximately 80-85% of patients; findings that are consistent with previous reports.14,17,19,25,26 Less commonly, gastrointestinal symptoms such as diarrhea were noted in one fifth of our study patients, similar to that reported in a multi-center Chinese study.27 Cardiovascular disease (ACS, decompensated heart failure, dysrhythmias, and myocarditis) was reported in 10% of our patients and may have had a negative impact on prognoses and outcomes due to resultant myocardial injuries.28,29 Differentiation between cardiac versus respiratory etiologies may be difficult for COVID-19 patients presenting with dyspnea or chest pain; however, recognizing the combined cardiovascular and pulmonary pathologies for this disease is critical for its management and prognosis.30

Although previous studies have illustrated the importance of clinical characteristics and the presence of risk factors in ICU-admitted patients,31,32 our study provides more comprehensive data regarding predictors for ICU admission and death in severely ill patients. The major predictors were advanced age, male gender, and the co-existence of multiple comorbidities. The latter has been shown to be linked to rapid progression of the disease and a higher risk for developing multi-organ failure and ARDS, which might require prolonged hospitalization and extensive support with ECMO.33,34

Laboratory investigations are also vitally important for the assessment of disease severity, and to guide disease management. Low hemoglobin levels, low platelet counts, prolonged INR levels, elevated cardiac enzymes, D-dimer levels, renal-function tests, and liver-function tests have all been reported as indicators for poor outcomes.35,36

Approximately 4.3% of the patients evaluated in this study died. Most deaths were due to ARDS and respiratory failure, and a previous study showed that ARDS was responsible for 53% of total COVID-19 deaths.37 The clinical implication for this study is that it provides insight for the major death and ICU admission predictors among COVID-19 patients in Saudi Arabia. This may help treating physicians to better triage patients and subsequently prioritize ICU admissions by identifying high-risk medical and clinical indicators.

Study limitations

First, although we obtained data from 768 patients in Saudi Arabia with laboratory-confirmed COVID-19, the analysis is based on a single center. More patients will be needed from other centers to provide more generalizable data. Second, we have reported baseline results from patients upon hospital admission; data from patients in home isolation or at hotels were not easily obtained.

In conclusion, despite these constraints, our data provides evidence that COVID-19 affects a wide variety of people, fever was consistently the most common early symptom, and both diabetes and hypertension were the most associated comorbidities. Certain patients with COVID-19, particularly smokers, obese or those who have history of lung disease, were in a critical risk of ICU admission. In high-risk populations, infection with SARS-Cov-2 can induce both systemic and pulmonary inflammation, leading to multiple organ dysfunction. Added to respiratory failure and acute respiratory distress syndrome, acute kidney injury and septic shock may also contribute to the critical illness state associated with high mortality. Fatality rate was 4.3%. Obesity, smoking, and diabetes mellitus were predictors of death in COVID-19 positive patients.

Acknowledgment

The authors gratefully acknowledge Cambridge Proofreading LLC for English language editing.

Footnotes

  • Disclosure. Authors have no conflict of interests, and the work was not supported or funded by any drug company.

  • Received August 19, 2020.
  • Accepted October 15, 2020.
  • Copyright: © Saudi Medical Journal

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

  1. ↵
    1. Song W,
    2. Gui M,
    3. Wang X,
    4. Xiang Y
    (2018) Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog 14:e1007236.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Wu Y,
    2. Chen C,
    3. Chan Y
    (2020) The outbreak of COVID-19:An overview. J Chin Med Assoc 83:217–20.
    OpenUrlCrossRefPubMed
    1. Cucinotta D,
    2. Vanelli M
    (2020) WHO declares COVID-19 a pandemic. Acta Biomed 91:157–160.
    OpenUrlPubMed
  3. ↵
    1. Sohrabi C,
    2. Alsafi Z,
    3. O'Neill N,
    4. Khan M,
    5. Kerwan A,
    6. Al-Jabir A,
    7. et al.
    (2020) World Health Organization declares global emergency:A review of the 2019 novel coronavirus (COVID-19). Int J Surg 76:71–76.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Perlman S
    (2020) Another Decade, another coronavirus. N Engl J Med 382:760–762.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Haleem A,
    2. Javaid M,
    3. Vaishya R,
    4. Deshmukh SG
    (2020) Areas of academic research with the impact of COVID-19. Am J Emerg Med 38:1524–1526.
    OpenUrlPubMed
  6. ↵
    1. Petrosillo N,
    2. Viceconte G,
    3. Ergonul O,
    4. Ippolito G,
    5. Petersen E
    (2020) COVID-19, SARS and MERS:are they closely related? Clin Microbiol Infect 26:729–734.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Xu X,
    2. Chen P,
    3. Wang J,
    4. Feng J,
    5. Zhou H,
    6. Li X,
    7. et al.
    (2020) Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 63:457–460.
    OpenUrlCrossRefPubMed
  8. ↵
    1. REUTERS
    Saudi Arabia announces first case of coronavirus, Updated 2020 March 2, Available form URL: https://www. reuters.com/article/us-health-coronavirus-saudi/saudi-arabia-announcesfirst-case-of-coronavirus-idUSKBN20P2FK. Accessed 2020 August.
  9. ↵
    1. Yang J,
    2. Zheng Y,
    3. Gou X,
    4. Pu K,
    5. Chen Z,
    6. Guo Q,
    7. et al.
    (2020) Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2:a systematic review and meta-analysis. Int J Infect Dis 94:91–95.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Chen T,
    2. Wu D,
    3. Chen H,
    4. Yan W,
    5. Yang D,
    6. Chen G,
    7. et al.
    (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368:m1091.
    OpenUrlAbstract/FREE Full Text
    1. Arentz M,
    2. Yim E,
    3. Klaff L,
    4. Lokhandwala S,
    5. Riedo F,
    6. Chong M,
    7. et al.
    (2020) Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State. JAMA 323:1612–1614.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Huang C,
    2. Wang Y,
    3. Li X,
    4. Ren L,
    5. Zhao J,
    6. Hu Y,
    7. et al.
    (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Guan W,
    2. Ni Z,
    3. Hu Y,
    4. Liang W,
    5. Ou C,
    6. He J,
    7. et al.
    (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382:1708–1720.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Huang X,
    2. Wei F,
    3. Hu L,
    4. Wen L,
    5. Chen K
    (2020) Epidemiology and clinical characteristics of COVID-19. Arch Iran Med 23:268–271.
    OpenUrl
  14. ↵
    1. Saudi Center for Disease Prevention Control, Ministry of Health Saudi Novel Corona Virus (2019-nCoV) Infection Guidelines V1.0
    , Update January 2020, Available from URL: https://www.moh.gov.sa/en/CCC/healthp/regulations/Documents/Novel%20Corona%20Virus%20Infection%20Guidelines.pdf. Accessed 2020 August.
  15. ↵
    1. Tian S,
    2. Hu N,
    3. Lou J,
    4. Chen K,
    5. Kang X,
    6. Xiang Z,
    7. et al.
    (2020) Characteristics of COVID-19 infection in Beijing. J Infect 80:401–406.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Zhu W,
    2. Xie K,
    3. Lu H,
    4. Xu L,
    5. Zhou S,
    6. Fang S
    (2020) Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei China. J Med Virol 92:1525–1532.
    OpenUrlPubMed
  17. ↵
    1. Chen N,
    2. Zhou M,
    3. Dong X,
    4. Qu J,
    5. Gong F,
    6. Han Y,
    7. et al.
    (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study. Lancet 395:507–513.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Oudit GY,
    2. Pfeffer MA
    (2020) Plasma angiotensin-converting enzyme 2:novel biomarker in heart failure with implications for COVID-19. Eur Heart J 41:1818–1820.
    OpenUrl
  19. ↵
    1. Zhou F,
    2. Yu T,
    3. Du R,
    4. Fan G,
    5. Liu Y,
    6. Liu Z,
    7. et al.
    (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study. Lancet 395:1054–1062.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Richardson S,
    2. Hirsch JS,
    3. Narasimhan M,
    4. Crawford JM,
    5. McGinn T,
    6. Davidson KW,
    7. et al.
    (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 323:2052–2059.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Kulcsar KA,
    2. Coleman CM,
    3. Beck SE,
    4. Frieman MB
    (2019) Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight 4:e131774.
    OpenUrl
  22. ↵
    1. Maddaloni E,
    2. Buzzetti R
    (2020) Covid-19, and diabetes mellitus:unveiling the interaction of two pandemics. Diabetes Metab Res Rev, e33213321.
  23. ↵
    1. Sun P,
    2. Qie S,
    3. Liu Z,
    4. Ren J,
    5. Li K,
    6. Xi J
    (2020) Clinical characteristics of hospitalized patients with SARS-CoV-2 infection:A single arm meta-analysis. J Med Virol 92:612–617.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Rodriguez-Morales AJ,
    2. Cardona-Ospina JA,
    3. Gutiérrez-Ocampo E,
    4. Villamizar-Peña R,
    5. Holguin-Rivera Y,
    6. Escalera-Antezana JP,
    7. et al.
    (2020) Clinical, laboratory and imaging features of COVID-19:A systematic review and meta-analysis. Travel Med Infect Dis 34:101623.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Pan L,
    2. Mu M,
    3. Yang P,
    4. Sun Y,
    5. Wang R,
    6. Yan J,
    7. et al.
    (2020) Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China. Am J Gastroenterol 115:766–773.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Aghagoli G,
    2. Gallo Marin B,
    3. Soliman LB,
    4. Sellke FW
    (2020) Cardiac involvement in COVID-19 patients:Risk factors, predictors, and complications:A review. J Card Surg 35:1302–1305.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Lippi G,
    2. Plebani M
    (2020) Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 58:1131–1134.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Fried JA,
    2. Ramasubbu K,
    3. Bhatt R,
    4. Topkara VK,
    5. Clerkin KJ,
    6. Horn E,
    7. et al.
    (2020) The variety of cardiovascular presentations of COVID-19. Circulation 141:1930–1936.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Wang Y,
    2. Lu X,
    3. Li Y,
    4. Chen H,
    5. Chen T,
    6. Su N,
    7. et al.
    (2020) Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 201:1430–1434.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Guan WJ,
    2. Liang WH,
    3. Zhao Y,
    4. Liang HR,
    5. Chen ZS,
    6. Li YM,
    7. et al.
    (2020) Comorbidity and its impact on 1590 patients with COVID-19 in China:a nationwide analysis. Eur Respir J 55:2000547.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Zaim S,
    2. Chong JH,
    3. Sankaranarayanan V,
    4. Harky A
    (2020) COVID-19 and multiorgan response. Curr Probl Cardiol 45:100618.
    OpenUrlCrossRefPubMed
  32. ↵
    1. MacLaren G,
    2. Fisher D,
    3. Brodie D
    (2020) Preparing for the most critically ill patients with COVID-19:The potential role of extracorporeal membrane oxygenation. JAMA 323:1245–1246.
    OpenUrl
  33. ↵
    1. Wang D,
    2. Hu B,
    3. Hu C,
    4. Zhu F,
    5. Liu X,
    6. Zhang J,
    7. et al.
    (2020) Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061–1069.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Zhang G,
    2. Hu C,
    3. Luo L,
    4. Fang F,
    5. Chen Y,
    6. Li J,
    7. et al.
    (2020) Clinical features, and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol 127:104364.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Ruan Q,
    2. Yang K,
    3. Wang W,
    4. Jiang L,
    5. Song J
    (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 05(46):846–848.
    OpenUrl
PreviousNext
Back to top

In this issue

Saudi Medical Journal: 41 (11)
Saudi Medical Journal
Vol. 41, Issue 11
1 Nov 2020
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical characteristics and in-hospital mortality of COVID-19 adult patients in Saudi Arabia
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
Clinical characteristics and in-hospital mortality of COVID-19 adult patients in Saudi Arabia
Samah I. Abohamr, Rami M. Abazid, Mubarak A. Aldossari, Hala A. Amer, Omar S. Badhawi, Obaid M. Aljunaidi, Shaimaa H. Alzarzour, Hiba M. Saadeddin, Fayaz A. Bhat, Eman Elsheikh
Saudi Medical Journal Nov 2020, 41 (11) 1217-1226; DOI: 10.15537/smj.2020.11.25495

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Clinical characteristics and in-hospital mortality of COVID-19 adult patients in Saudi Arabia
Samah I. Abohamr, Rami M. Abazid, Mubarak A. Aldossari, Hala A. Amer, Omar S. Badhawi, Obaid M. Aljunaidi, Shaimaa H. Alzarzour, Hiba M. Saadeddin, Fayaz A. Bhat, Eman Elsheikh
Saudi Medical Journal Nov 2020, 41 (11) 1217-1226; DOI: 10.15537/smj.2020.11.25495
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The interaction between no folic acid supplementation during early pregnancy and preeclampsia increased the risk of preterm birth
  • The characteristics of Grave’s disease in children and adolescent patients in Al-Madinah Al-Munawwarah
  • Patellar height changes after treatment of tibia plateau fractures
Show more Original Article

Similar Articles

Keywords

  • COVID-19
  • in-hospital
  • clinical characteristics
  • mortality
  • Saudi Arabia

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2023 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire